Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

June 12, 2024 4:01 PM EDT

SAN DIEGO, June 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common... More

Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People L

June 12, 2024 7:00 AM EDT

Avidity plans to accelerate the initiation of registrational cohorts in FORTITUDE trial

Delpacibart braxlosiran (AOC 1020), the first investigational therapy to target the underlying cause of FSHD, provided greater than 50% mean reduction across multiple DUX4 regulated gene panels (2 mg/kg at four months)

Trends of functional improvement including muscle strength, reachable workspace, and positive trends in patient and clinician reported outcomes demonstrated in people treated with delpacibart braxlosiran 2 mg/kg at four months

Delpacibart braxlosiran data demonstrate favorable safety... More